OncoViews
  • Therapy Areas
  • Latest
  • CHECK-IN NOW
Antibody-Drug Conjugates in Breast Cancer: Advancing Precision Treatment

Antibody-Drug Conjugates in Breast Cancer: Advancing Precision Treatment

by PEAK Medicals | 25 April 2025 | Antibody Drug Conjugates, Women's Cancers

With an estimated 2.3 million cases diagnosed annually, breast cancer continues to be the most common cancer among women globally (1). Despite rising incidence rates, improvements in early detection and targeted therapy have caused mortality rates to decline. Among...
Endometrial Cancer: A Revolution That Is Only Just Beginning

Endometrial Cancer: A Revolution That Is Only Just Beginning

by Ilaria Colombo | 25 February 2025 | Women's Cancers

Immunotherapy has set new standards in the management of advanced endometrial cancer. In addition, antibody-drug conjugates have shown promising activity in the pre-treated setting, suggesting further paradigm shifts in the future. In the last two years, first-line...
Advanced Ovarian Cancer: In Search of the Ideal Strategy

Advanced Ovarian Cancer: In Search of the Ideal Strategy

by Christina Fotopoulou | 12 February 2025 | Women's Cancers

Systemic treatment of ovarian cancer has improved significantly over the last thirteen years thanks to the introduction of targeted substances such as PARP inhibitors. Nevertheless, further research is needed, as recurrences are frequent, and identifying the optimal...
CHMP Recommends Approval of Three Promising Therapies in the EU

CHMP Recommends Approval of Three Promising Therapies in the EU

by EMA Approval | 3 February 2025 | Lung Cancer, Women's Cancers

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recently recommended the approval of three therapeutic approaches, marking significant progress in the treatment of lung cancer, breast cancer, and cervical cancer and...
New Perspectives In The Early And Late Stages Of Cervical Cancer

New Perspectives In The Early And Late Stages Of Cervical Cancer

by Apostolos Sarivalasis | 22 January 2025 | Women's Cancers

As with other types of cancer, the therapeutic landscape for cervical cancer has been transformed by immunotherapy, but changes are taking place in various strategic areas. Innovative approaches are expanding the algorithms for locally advanced and metastatic disease....
FDA Approves Dato-DXd for Advanced HR-Positive, HER2-Negative Breast Cancer

FDA Approves Dato-DXd for Advanced HR-Positive, HER2-Negative Breast Cancer

by FDA Approval | 20 January 2025 | Women's Cancers

On January 17, 2025, the US Food and Drug Administration (FDA) approved datapotamab deruxtecan-dlnk (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, human...
« Older Entries

Recent Posts

  • Antibody-Drug Conjugates in Breast Cancer: Advancing Precision Treatment
  • Diagnosis of Lung Cancer: Biomarker Testing on the Road to the Future
  • Advancing Frontline Treatment: Managing Enfortumab Vedotin and Pembrolizumab Toxicities in Metastatic Urothelial Cancer
  • Endometrial Cancer: A Revolution That Is Only Just Beginning
  • Advanced Ovarian Cancer: In Search of the Ideal Strategy

Recent Comments

No comments to show.

Share your patient case for discussion

Let our faculty discuss your patient case during the roundtables - rest assured, we'll keep you posted!

submit patient case

Quick Links

Twitter
LinkedIn
Contact
Terms Of Use
Privacy Policy
Legal Notice

Our Partners

Leading Opinions

Choose your area of interest

Join our network and become an OncoViewer!

SIGN UP FOR FREE
Lung Icon

Lung Cancer

NSCLC, Mesothelioma, SCLC
Uterus Icon

Women's Cancers

Breast Cancer, Gynecologic Cancers
GI Icon

Gastrointestinal

Upper & Lower GI, Pancreatic, HCC
Bladder Icon

Urogenital

Renal, Urothelial & Prostate
Hematology Icon

Hematology

Hodgkin- & Non-Hodgkin Lymphomas
Other Solid Tumor Icon

Other Solid Tumors

Melanoma, Head & Neck Cancer, etc

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}